These data suggest that high numbers of PD-L1+ cells in the bladder could suppress the effectiveness of BCG, a hypothesis also supported by the recent demonstration that combined BCG and anti-PD-L1 treatment increased antitumor immunity in an immunocompetent orthotopic rat bladder cancer model [19]. This evidence concerns the gene CD274 and urinary bladder carcinoma.